Document:

<PAGE>

                         OFFICER'S EMPLOYMENT AGREEMENT

         EMPLOYMENT AGREEMENT, dated as of September 15 2001, between H Power
Corp., a Delaware corporation, having its principal place of business at 60
Montgomery Street, Belleville, New Jersey 07109 (hereinafter referred to as the
"Company"), and Paul McNeill, residing at Mountain View Crossing Apt. 2301 Wayne
NJ 07470 (hereinafter referred to as "Executive"). (The Company and Executive
are collectively referred to as the "Parties.")

1. TERM OF EMPLOYMENT

         Subject to the provisions of this employment agreement, the Company
hereby agrees to employ Executive, and Executive hereby agrees to be employed by
the Company, for a term commencing September 15, 2001 and ending September 15,
2004 (the "Term"). This contract will renew automatically in one year increments
unless written notice is given by either party of an intent to terminate the
contract within six months of the expiration date then in effect for the
contract.

2. TITLES AND DUTIES

         Subject at all times to the supervision and direction of the Chief
Executive Officer of the Company (the "CEO"), Executive shall be employed as
Vice President, Business Development, and shall have such duties, authority,
rights and obligations as are usually inherent in such position and as the CEO
may reasonably require. In general, Executive shall use his very best efforts to
promote the business of the Company. In the event that Executive is elected or
appointed as a Director or an Officer of the Company's affiliated or subsidiary
companies, whether now existing or hereafter acquired, Executive consents to
serve in such capacity or capacities as the CEO may determine, without
additional compensation.

         Executive shall render his services at the Company's principal place of
business or at such other place or places as the Board shall designate.

3. EXCLUSIVE EMPLOYMENT

         Executive shall devote substantially all his business time, ability and
attention to the business of H Power. Executive shall not directly or indirectly
render any services of a business, commercial, or professional nature to any
other person or organization, whether for compensation or otherwise, that is in
competition directly or indirectly with the business of H Power.

4. COMPENSATION & BENEFITS

         For the full and faithful performance of his services as set forth
hereunder, Executive shall be entitled to the following:

<PAGE>

         (a)  Base Salary. During the Term, Executive shall be paid an annual
              salary of $135,000.00, payable in bi-weekly installments, subject
              to all applicable withholding, social security and other payroll
              taxes.

         (b)  Salary Adjustments. The rate of salary shall be reviewed by the
              Board not less often than annually and may be increased (but not
              decreased) from time to time in such amounts as the Board in its
              discretion may provide; it being understood, however, that the
              Board shall have no obligation to increase said salary.

         (c)  Benefit Programs. Executive shall be entitled to participate in
              all employee benefit programs of the Company available to senior
              executives of the Company, as such programs may be in effect from
              time to time, including, without limitation: pension or other
              retirement plans; profit sharing plans; group life insurance;
              accidental death and dismemberment insurance; hospitalization,
              surgical and major medical coverage; sick leave, vacation and
              holiday benefits; and other employee benefit programs sponsored by
              the Company; provided, however, that there is no obligation on the
              part of the Company to provide these benefits to senior
              executives. Such programs may be amended or terminated if done so
              for all or a material portion of the Company's executives.

         (d)  Business Expense Reimbursement. Executive shall be entitled to
              receive reimbursement from the Company for all reasonable and
              actual out-of-pocket expenses incurred by him (in accordance with
              the policies and procedures established by the Company) in
              performing services during his employment, provided that Executive
              timely submits reasonable documentation with respect to such
              expenses.

         (e)  Bonuses. In addition to all other compensation, Executive shall be
              entitled to receive such bonuses as the Board shall determine, in
              its sole discretion, from time to time; it being understood that
              the Board shall have no obligation to award such bonuses.

         (f)  Automobile. Executive shall be entitled to an automobile allowance
              of seven thousand five hundred dollars ($7,500) per annum.

         (g)  Stock Options. Executive shall be granted five-year stock options
              to purchase 75,000 shares of the Company's Common Stock, par value
              $.001 per share, at a price equal to the fair market value of the
              Common Stock on September 17, 2001, pursuant to the H Power Corp.
              2000 Stock Option Plan. The options may be exercised as follows:
              one-third as of September 17, 2002, one-third as of September 17,
              2003, and the final third as of September 17, 2004.

5. TERMINATION OF EMPLOYMENT

         (a)  For Cause. The Company shall have the right to terminate this
              employment agreement immediately after written notification to
              Executive specifying the basis

                                       2

<PAGE>

              for the termination, upon the occurrence of any one of the
              following events which shall constitute "cause": (i) the willful
              failure by Executive to abide by the terms of this employment
              agreement; or (ii) fraud, misappropriation, embezzlement, theft,
              dishonesty or similar actions by Executive; or (iii) the habitual
              or willful neglect by Executive of his employment duties; or (iv)
              an act of moral turpitude by Executive which tends to reflect
              unfavorably on the Company.

                     In the event that the Company terminates Executive's
              employment for cause, Executive shall be entitled only to the
              unpaid bi-weekly installments of his Base Salary up to and
              including the date of termination and to his approved Business
              Expense Reimbursement not paid prior to termination.

         (b)  In the Event of Death. This employment agreement shall terminate
              in the event of Executive's death, in which case Executive's
              estate shall be entitled to the bi-weekly installments of
              Executive's Base Salary for a period of six months following the
              date of death and Executive's Business Expense Reimbursement not
              paid prior to his death.

         (c)  In the Event of Disability. The Company shall have the right to
              terminate this employment agreement in the event of Executive's
              inability to substantially perform his duties hereunder for a
              period of three months out of any six-month period during his
              employment, whether such inability results from illness, accident
              or otherwise.

                     In the event that the Company terminates Executive's
              employment during the term of this employment agreement as a
              result of Executive's Disability, Executive shall be entitled to
              the bi-weekly installments of his Base Salary for a period of six
              months following the date of termination; Executive's Business
              Expense Reimbursement not paid prior to termination; and the
              continuation of Executive's health and welfare benefits through
              the end of the term of this employment agreement.

         (d)  Change in Control. (i) In the event that Executive's employment is
              terminated by the Company within one year following a Change in
              Control (as defined below) for any reason other than cause, death
              or disability, then the Company shall pay Executive one-half his
              annual Base Salary at his then current rate and one-half of the
              latest annual incentive compensation payment calculated by taking
              the highest of the latest two incentive payments earned and paid
              divided by two, such payment to be made in one lump sum payment at
              the time of termination. Such payments shall be in lieu of any and
              all other payments due and owing to Executive under the terms of
              this Agreement. The Company shall also provide to the Executive
              health insurance for a period of one year following termination of
              Executive's employment. Executive shall not be required to seek
              other employment or to otherwise mitigate the effects of such
              termination, and such payments shall not be reduced by any income
              received from other sources (all compensation and other benefits
              described above and the terms thereof shall hereinafter be
              referred to collectively as the "Severance Package").

                                       3

<PAGE>

                     (ii) Executive may terminate his employment hereunder
              within one year following a Change of Control for Good Reason;
              provided that, (x) the Company has been given notice setting forth
              in reasonable detail the nature of the Good Reason and (y) a
              period of at least thirty (30) days in which the Company may
              remedy the circumstances giving rise to such Good Reason has
              expired, and the Company fails to so remedy such circumstances.
              For purposes of this Agreement, "Good Reason" shall mean:

                                (A) the assignment to Executive of any duties
                     materially inconsistent with Executive's position, duties
                     and responsibilities as set forth in Section 2 of this
                     Agreement or any action by the Company which results in a
                     material diminution in Executive's position, authority,
                     duties or responsibilities, excluding for this purpose any
                     isolated or inadvertent action by the Company which is
                     remedied by the Company promptly after receipt of notice
                     thereof from the Executive; or

                                (B) any failure by the Company to comply in all
                     material respects with the provisions of Section 4 of this
                     Agreement regarding Executive's compensation, benefits,
                     vacation, and expenses other than an isolated or
                     inadvertent action by the Company which is remedied by the
                     Company promptly after receipt of notice thereof from the
                     Executive.

              In the event that Executive terminates his employment for Good
              Reason following a Change in Control, then the Company shall pay
              Executive the Severance Package.

                     For purposes of this provision, a "Change in Control" shall
              be deemed to have occurred: (i) if any "person" (as such term is
              used in Sections 13(d)(3) and 14(d)2) of the Securities Exchange
              Act of 1934, as amended (the "Exchange Act")), other than
              Executive, who is not a shareholder of the Company as of the date
              hereof, shall have become the beneficial owner, directly or
              indirectly, of Common Stock representing thirty-three and
              one-third percent (33-1/3%) or more of the combined voting power
              of of the Company's then outstanding securities, unless
              three-quarters of the Board of Directors, as constituted
              immediately prior to the date of the Change in Control, decide in
              their reasonable discretion that no Change in Control has
              occurred, the Executive not being allowed to vote on such matter
              if he is then a Director; provided, however, that if any such
              person other than Executive (whether or not a stockholder of the
              Company as of the date hereof) shall become the beneficial owner,
              directly or indirectly, of Common Stock representing fifty percent
              (50%) or more of the Company's then outstanding securities, a
              Change in Control shall ipso facto have occurred; or (ii) if there
              is a Change in Control of a nature that, in the opinion of counsel
              for the Company, would be required to be reported in response to
              Item 6(e) of schedule 14A under the Exchange Act, unless
              three-quarters of the Board of Directors, as constituted
              immediately prior to the date of the Change in Control, decide in
              their reasonable discretion that no Change in Control has
              occurred, Executive not being allowed to vote on such matter if he
              is then a Director.

                                       4

<PAGE>

6. UNAUTHORIZED DISCLOSURE

         During the period of his employment and for a period of three (3) years
thereafter, Executive shall not, without the prior written consent of the Board,
disclose to any person other than as required by law or court order (10 days'
prior written notice having been given to the Company in order to formulate a
response), or other than to an employee of the Company, or to a person to whom
disclosure is necessary or appropriate in connection with the performance by
Executive of his duties as an executive of the Company, any confidential
information obtained by him while in the employ of the Company with respect to
any of the Company's products, services, customers, suppliers, marketing
techniques, patents, proprietary technologies, trade secrets, methods, or future
plans, the disclosure of which will be damaging to the Company; provided,
however, that confidential information shall not include any information known
generally to the public (other than as a result of unauthorized disclosure by
Executive).

7. RESTRICTIVE COVENANT

         During the period of his employment and for a period of two (2) years
thereafter, Executive shall not enter into competition with the Company or any
affiliate of the Company without the prior consent of the Board. For the purpose
of this paragraph 7, competition shall mean the association of Executive with a
company, corporation, firm or partnership, whether as an employee, consultant,
partner, principal, agent, representative or shareholder, directly or indirectly
(except as a holder, directly or indirectly, of less than Five (5%) Percent of
the outstanding securities of any corporation whose stock is listed for trading
on any securities exchange or are traded in the over-the-counter market), which
competes, directly or indirectly, with the Company in any business in which the
Company is presently engaged, including but not limited to the development,
marketing, manufacturing, or distribution of fuel cell system, or will be
engaged upon termination of Executive's employment, unless such association
shall be for purposes and shall impose duties upon Executive that do not
directly relate to the Company's business activities. If a court of competent
jurisdiction should determine that the period, scope, or geographical area of
the restrictions set forth in this paragraph 7 are unreasonable under the
circumstances then existing, the Parties agree that the period, scope, or
geographical area that is reasonable under such circumstances shall be
substituted for the stated period, scope, or geographical area.

         During the Term and for a period of two (2) years thereafter, Executive
shall neither solicit, induce and/or suggest to any of the employees,
consultants to, or other persons having a substantial contractual relation with,
the Company to leave such employ, cease consulting or terminate such contractual
relationship with the Company nor to join Executive as a partner, co-venturer,
employee, investor, or otherwise, in any substantial business activity
whatsoever.

         Executive shall at no time take any action or make any statement that
could discredit the reputation of the Company or its personnel, products or
services.

8. INVENTIONS OR DISCOVERIES

         Executive shall fully and promptly disclose to the Company any and all
improvements, discoveries, and inventions made or conceived by him, whether or
not patentable, whether or not

                                       5

<PAGE>

during the working hours of his employment or with the use of the Company's
facilities, materials or personnel, and whether solely or jointly with others,
during his employment by the Company, which result from or relate to the
business of the Company in any way.

         Any and all such improvements, discoveries, and inventions are and
shall remain the sole and exclusive property of the Company without royalty or
payment of any further consideration to Executive, on his own behalf and on the
behalf of his heirs, assigns, executors, administrators, and any other legal
representative. Executive hereby assigns and transfers all of his right, title
and interest in and to all such improvements, discoveries, and inventions to the
Company, including, but not limited to, any applications for United States
and/or foreign letter patents and any United States and/or foreign patents that
shall be granted. Executive shall apply, at the Company's request and expense,
for United States and foreign letters patent, whether in his name or otherwise
as the Company shall desire, and shall execute and deliver to the Company
without charge to the Company, but at its expense, such written instruments and
shall do such other acts as may be necessary or appropriate in the opinion of
the Company to obtain and maintain United States and/or foreign letters patent
or other proprietary rights and shall vest the entire right entitled thereto in
the Company.

9. EQUITABLE RELIEF

         Executive hereby represents that the services to be performed by him
are of a special, unique, unusual, extraordinary and intellectual character
which gives them a peculiar value, the loss of which cannot be reasonably or
adequately compensated in damages in an action at law and that any violation of
this employment agreement will cause the Company immediate and irreparable harm.
Executive therefore expressly agrees that, in addition to any other rights or
remedies which the Company may possess, the Company shall be entitled to
injunctive and other equitable relief to prevent a breach of this contract by
the Company.

10. INDEMNIFICATION

         Executive shall indemnify and save harmless the Company from all
liability from loss, damage or injury to persons or property resulting from the
gross negligence or willful misconduct of Executive.

11. ASSIGNABILITY

         No rights or obligations under this employment agreement may be
assigned or transferred by Executive except:

         (a)  Executive's rights to compensation and benefits hereunder shall,
              in the event of death, pass to his estate, or to his designated
              beneficiary and may be transferred by will or operation of law,
              and

         (b)  Executive's rights under the Company's plans, programs and
              policies may be assigned or transferred in accordance with the
              terms of such plans, programs and policies.

                                       6

<PAGE>

         The rights and obligations of the Company under this employment
agreement shall inure to the benefit of and shall be binding upon the successors
and assigns of the Company. The Company shall have the right to assign this
agreement to a successor in the event of a merger, consolidation, sale of a
substantial portion of its assets or a similar transaction.

12. GOVERNING LAW

         This employment agreement shall be governed by the laws of the State of
New Jersey without reference to the principles of conflict of laws.

13. ENTIRE AGREEMENT

         Except as otherwise specifically provided herein, this employment
agreement contains all the legally binding understandings and representations
between the Company and Executive pertaining to the subject matter hereof and
supersedes all undertakings and agreements, if any, whether oral or in writing,
previously entered into by the Company and Executive with respect to such
subject matter.

14. AMENDMENT OR MODIFICATION; WAIVER

         No provision of this employment agreement may be amended or waived
unless such amendment or waiver is approved by the Board and is signed by
Executive and by a duly authorized officer of the Company. Except as otherwise
specifically provided in this employment agreement, no waiver by the Company or
Executive of any breach by the other of any condition or provision of this
employment agreement to be performed by such other party shall be deemed a
waiver of a similar or dissimilar provision or condition at the same or any
prior or subsequent time.

15. NOTICES

         Any notice required or permitted to be given under this employment
agreement shall be in writing and shall be deemed to have been given when
delivered personally or sent by certified or registered mail, postage prepaid,
return receipt requested, duly addressed to the party concerned at the address
indicated below or to such changed address as such party may subsequently give
notice of:

                          If to H Power:      H Power Corp.
                                              60 Montgomery Street
                                              Belleville, New Jersey  07109
                                              Attn.: Secretary

                          If to Executive:    Paul McNeill
                                              Mountain View Crossing
                                              Apt 2301
                                              Wayne NJ 07470

                                       7
<PAGE>

16. SEVERABILITY

         In the event that any provision or portion of this employment agreement
shall be determined to be invalid or unenforceable for any reason, the remaining
provisions or portions of this employment agreement shall be unaffected thereby
and shall remain in full force and effect to the fullest extent permitted by
law.

17. SURVIVORSHIP

         To the extent contemplated by this employment agreement, the respective
rights and obligations of the Parties hereunder shall survive any termination of
this employment agreement to the extent necessary to the intended preservation
of such rights and obligations.

18. REPRESENTATIONS

         (a)  By the Executive. Executive represents and warrants that the
              performance of his duties under this employment agreement will not
              violate any agreement between him and any other person, firm or
              organization.

         (b)  By the Company. The Company represents and warrants that it is
              fully authorized and empowered to enter into this employment
              agreement.

19. REFERENCES

         In the event of Executive's death or a judicial determination of his
incompetence, reference in this employment agreement to Executive will be
deemed, where appropriate, to refer to his legal representative or, where
appropriate, to his beneficiary or beneficiaries.

         Headings to the sections in this agreement are intended solely for
convenience and no provision of this employment agreement shall be construed by
reference to any heading.

20. MUTUAL INTENT

         The language used in this employment agreement is the language chosen
by the Parties to express their mutual intent. The Parties agree that in the
event that any language, section, clause, phrase or word used in this employment
agreement is determined to be ambiguous, no presumption shall arise against or
in favor of either party and that no rule of strict construction shall be
applied against either party.

                                       8

<PAGE>

         IN WITNESS WHEREOF, Executive and the Company have caused this
employment agreement to be executed as of the day and year first above written.

EXECUTIVE                                     H POWER CORP.

/s/ Paul McNeill                              By: /s/ H. Frank Gibbard
--------------------------                        -----------------------------
Paul McNeill                                      H. Frank Gibbard
                                                  Chief Executive Officer

                                      9<PAGE>
                                                                    EXHIBIT 10.2

                            STOCK EXCHANGE AGREEMENT

         THIS STOCK EXCHANGE AGREEMENT (the "Agreement") is made and entered
into this 13th day of April, 2001 by and among BIOMED RESEARCH TECHNOLOGIES,
INC., a Delaware corporation (hereinafter referred to as "BioMed"), SURE
MEDICAL, INCORPORATED, a Nevada corporation (hereinafter referred to as "Sure"),
DR. WILLIAM STAFFORD, the principal shareholder of Sure through his interest in
My-Tech, Inc. ("Stafford") and the shareholders of Sure listed on the
counterpart signature pages hereto constituting all of the shareholders of Sure
(hereinafter collectively with Stafford referred to as the "Sure Shareholders").

                                    RECITALS:

         A. The Sure Shareholders own all of the issued and outstanding shares
of the capital stock of Sure.

         B. BioMed is willing to acquire all of the issued and outstanding
capital stock of Sure, making Sure a wholly-owned subsidiary of BioMed, and the
Sure Shareholders desire to exchange all of their shares of Sure's capital stock
for authorized but unissued shares of Common Stock, par value $.001 per share
(the "Common Stock") of BioMed as hereinafter provided.

         C. It is the intention of the parties hereto that: (i) BioMed shall
acquire all of the issued and outstanding capital stock of Sure in exchange
solely for the consideration set forth below (the "Exchange"); and (ii) the
Exchange shall qualify as a transaction in securities exempt from registration
or qualification under the Securities Act of 1933, as amended, and under the
applicable securities laws of each jurisdiction where the Sure Shareholders
reside.

         D. It is the intention of the parties that the Exchange qualify as a
"tax-free" transaction within the meaning of Section 368 of the Internal Revenue
Code of 1986.

         NOW, THEREFORE, in consideration of the mutual covenants, agreements,
representations and warranties contained in this Agreement, the parties hereto
agree as follows:

SECTION 1.  PURCHASE OF SHARES

         1.1 ACQUISITION OF SHARES. BioMed and the Sure Shareholders hereby
agree that the Sure Shareholders shall, on the Closing Date (as hereinafter
defined), exchange an aggregate of 4,730,250 shares of the Common Stock of Sure
which constitute all of the issued and outstanding shares of capital stock of
Sure (the "Sure Shares") and BioMed shall issue to the Sure Shareholders an
aggregate of 3,230,000

                                       1
<PAGE>

Shares of BioMed's Common Stock (the "BioMed Shares"). The allocation of the
BioMed Shares to the Sure Shareholders is set forth on Exhibit A hereto.

         1.2 DELIVERY OF SURE SHARES. On the Closing Date, the Sure Shareholders
will deliver to BioMed the certificates representing the Sure Shares, duly
endorsed (or with executed stock powers) so as to make BioMed the sole owner
thereof. Simultaneously, BioMed will deliver certificates representing the
BioMed Shares to the Sure Shareholders.

         1.3 INVESTMENT INTENT. The BioMed Shares have not been registered under
the Securities Act of 1933, as amended (the "Act"), and may not be resold unless
the BioMed Shares are registered under the Act or an exemption from such
registration is available. The Sure Shareholders represent and warrant that each
of them is acquiring the BioMed Shares for his, her or its own account, for
investment, and not with a view to the sale or distribution of the BioMed
Shares. Each certificate representing the BioMed Shares will have a legend
thereon incorporating language as follows:

         "The shares represented by this certificate have not been registered
         under the Securities Act of 1933, as amended (the "Act") or any state
         securities laws. The shares have been acquired for investment and may
         not be sold or transferred in the absence of an effective Registration
         Statement for the shares under the Act unless in the opinion of counsel
         satisfactory to the Company, registration is not required under the Act
         or any applicable state securities laws."

SECTION 2.  REPRESENTATIONS AND WARRANTIES OF SURE, STAFFORD AND
            SURE SHAREHOLDERS

         Sure, Stafford and the Sure Shareholders hereby represent and warrant
as follows (except that with respect to the Sure Shareholders other than
Stafford, such representations and warranties shall be to the best of their
knowledge other than with respect to Section 2.2 below):

         2.1 ORGANIZATION AND GOOD STANDING. Sure is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Nevada, and is entitled to own or lease its properties and to carry on its
business as and in the places where such properties are now owned, leased or
operated and such business is now conducted. Sure is qualified to do business as
a foreign corporation in each jurisdiction, if any, in which its property or
business requires such qualification. Sure does not have any subsidiaries.

         2.2 OWNERSHIP OF SURE SHARES AND AUTHORIZATION OF AGREEMENT. The Sure
Shareholders represent as to his, her or their respective ownership of Sure
Shares, that he, she or they are the owner of record and beneficially of all of
the shares of capital stock of Sure listed in their respective names on Exhibit
A hereto, all of which shares are free and clear of all rights, claims, liens
and encumbrances, and have not been sold, pledged,

                                       2
<PAGE>

assigned or otherwise transferred except pursuant to this Agreement. There are
no outstanding subscriptions, rights, options, warrants or other agreements
obligating either Sure or the Sure Shareholders to issue, sell or transfer any
stock or other securities of Sure. The Sure Shareholders have the power to enter
into this Agreement and to carry out the obligations hereunder. This Agreement
has been duly executed by each Sure Shareholder, or its authorized
representative, and constitutes the valid and binding obligation of each Sure
Shareholder and is enforceable against each Sure Shareholder in accordance with
its terms.

         2.3 FINANCIAL STATEMENTS, BOOKS AND RECORDS. There has been previously
delivered to BioMed the [audited] balance sheet of Sure as of December 31, 2000
(the "Balance Sheet") and the related statement of operations for the period
then ended (collectively the "Financial Statements"). The Financial Statements
fairly represent the financial position of Sure as at such date and the results
of its operations for the period then ended.

         2.4 NO MATERIAL ADVERSE CHANGES. Since the date of the Balance Sheet
there has not been:

                  (i) any material adverse change in the assets, operations,
condition (financial or otherwise) or prospective business of Sure;

                  (ii) any damage, destruction or loss materially affecting the
assets, prospective business, operations or condition (financial or otherwise)
of Sure, whether or not covered by insurance;

                  (iii) any declaration, setting aside or payment of any
dividend or distribution with respect to any redemption or repurchase of Sure's
capital stock;

                  (iv) any sale of an asset (other than in the ordinary course
of business) or any mortgage or pledge by Sure of any properties or assets; or

                  (v) adoption of any pension, profit sharing, retirement, stock
bonus, stock option or similar plan or arrangement.

         2.5 COMPLIANCE WITH LAWS. Sure has complied with all federal, state,
county and local laws, ordinances, regulations, inspections, orders, judgments,
injunctions, awards or decrees applicable to it or its business which, if not
complied with, would materially and adversely affect the business of Sure.

         2.6 NO BREACH. The execution, delivery and performance of this
Agreement and the consummation of the transactions contemplated hereby will not:

                  (i) violate any provision of the Charter or By-Laws of Sure;

                                       3
<PAGE>

                  (ii) violate, conflict with or result in the breach of any of
the terms of, result in a material modification of, otherwise give any other
contracting party the right to terminate, or constitute (or with notice or lapse
of time or both constitute) a default under, any contract or other agreement to
which Sure is a party or by or to which it or any of its assets or properties
may be bound or subject;

            (iii) violate any order, judgment, injunction, award or decree of
any court, arbitrator or governmental or regulatory body against, or binding
upon, Sure, or upon the properties or business of Sure; or

             (iv) violate any statute, law or regulation of any jurisdiction
applicable to the transactions contemplated herein which could have a materially
adverse effect on the business or operations of Sure.

         2.7 ACTIONS AND PROCEEDINGS. There is no outstanding order, judgment,
injunction, award or decree of any court, governmental or regulatory body or
arbitration tribunal against or involving Sure. There is no action, suit or
claim or legal, administrative or arbitral proceeding or (whether or not the
defense thereof or liabilities in respect thereof are covered by insurance)
bankruptcy, criminal, civil or regulatory proceeding pending or threatened
against or involving Sure or any of its properties, assets or shares of Common
Stock. Except as set forth on Schedule 2.7, there is no fact, event or
circumstances that may give rise to any suit, action, claim, investigation or
proceeding.

         2.8 BROKERS OR FINDERS. No broker's or finder's fee will be payable by
Sure in connection with the transaction contemplated by this Agreement, nor will
any such fee be incurred as a result of any actions by Sure or the Sure
Shareholders.

         2.9 REAL ESTATE. Sure neither owns real property nor is a party to any
leasehold agreement.

         2.10 TANGIBLE ASSETS. Sure has full title and interest in all
machinery, equipment, furniture, leasehold improvements, fixtures, vehicles,
structures, owned or leased by Sure, any related capitalized items or other
tangible property material to the business of Sure (the "Tangible Assets"). Sure
holds all rights, title and interest in all the Tangible Assets owned by it on
the Balance Sheet or acquired by it after the date of the Balance Sheet free and
clear of all liens, pledges, mortgages, security interests, conditional sales
contracts or any other encumbrances except as set forth on Schedule 2.10.

         2.11 LIABILITIES. Sure does not have any material direct or indirect
indebtedness, liability, claim, loss, damage, deficiency, obligation or
responsibility, known or unknown, fixed or unfixed, liquidated or unliquidated,
secured or unsecured, accrued or absolute, contingent or otherwise, (all of the
foregoing collectively defined to as "Liabilities"), which were not fully,
fairly and adequately reflected on the Balance Sheet. As of the Closing Date,
Sure will not have any Liabilities, other than Liabilities fully and adequately
reflected on the Balance Sheet, except for Liabilities incurred in the ordinary
course of business.

                                       4
<PAGE>

         2.12 OPERATIONS OF SURE. Except as set forth on Schedule 2.12, from the
date of the Balance Sheet and through the Closing Date hereof Sure has not and
will not have:

                  (i) incurred any indebtedness for borrowed money;

                  (ii) declared or paid any dividend or declared or made any
distribution of any kind to any shareholder, or made any direct or indirect
redemption, retirement, purchase or other acquisition of any shares in its
capital stock;

                  (iii) made any material loan or advance to any shareholder,
officer, director, employee, consultant, agent or other representative or made
any other material loan or advance otherwise than in the ordinary course of
business;

                  (iv) except in the ordinary course of business, incurred or
assumed any material indebtedness or liability (whether or not currently due and
payable);

                  (v) disposed of any assets of Sure except in the ordinary
course of business; or

                  (vi) issued any equity securities or rights to acquire such
equity securities.

         2.13 CAPITALIZATION. The authorized capital stock of Sure consists of
50,000,000 shares of common stock of which 4,730,250 shares are presently issued
and outstanding. Neither Sure nor the Sure Shareholders have granted, issued or
agreed to grant, issue or make available any warrants, options, subscription
rights or any other commitments of any character relating to the issued or
unissued shares of capital stock of Sure. All of the Sure Shares are duly
authorized and validly issued, fully paid and non-assessable.

         2.14     INTELLECTUAL PROPERTY.

                  (i)      Except to the extent that the inaccuracy of any of
                           the following (or the circumstances giving rise to
                           such inaccuracy) does not have or could not
                           reasonably be expected to have a material adverse
                           effect:

                           (A) Sure owns, or is licensed or otherwise has the
legally enforceable right to use (in each case, clear of any liens or
encumbrances of any kind), all Intellectual Property (as hereinafter defined)
used in or necessary for the conduct of its business as currently conducted;

                           (B) no claims are pending or, to the best knowledge
of Sure, threatened that Sure or any of its subsidiaries is infringing on or
otherwise violating the rights of any person with regard to any Intellectual
Property used by, owned by, and/or licensed to Sure, and to the best knowledge
of Sure, there are no valid grounds for any such claims;

                                       5
<PAGE>

                           (C) to the best knowledge of Sure, no person is
infringing on or otherwise violating any right of Sure with respect to any
Intellectual Property owned by and/or licensed to Sure;

                           (D) to the best knowledge of Sure, there are no valid
grounds for any claim challenging the ownership or validity of any Intellectual
Property owned by Sure or challenging Sure's license or legally enforceable
right to use any Intellectual Property licensed by it; and

                           (E) to the best knowledge of Sure, all patents,
registered trademarks, service marks, and copyrights held by Sure are valid and
subsisting.

                  (ii) For purposes of this Agreement, "Intellectual Property"
means trademarks (registered or unregistered), service marks, brand names,
certification marks, trade dress, assumed names, trade names, and other
indications of origin, the goodwill associated with the foregoing and
registrations in any jurisdiction of, and applications in any jurisdiction to
register, the foregoing, including any extension, modification or renewal of any
such registration or application; inventions, discoveries and ideas, whether
patented, patentable, or not in any jurisdiction; trade secrets and confidential
information and rights in any jurisdiction to limit the use or disclosure
thereof by any person; writings and other works of authorship, whether
copyrighted, copyrightable, or not in any jurisdiction; registration or
applications for registration of copyrights in any jurisdiction, and any
renewals or extensions thereof; any similar intellectual property or proprietary
rights and computer programs and software (including source code, object code,
and data); licenses, immunities, covenants not to sue, and the like relating to
the foregoing; and any claims or causes of action arising out of or related to
any infringement or misappropriation of any of the foregoing.

                  (iii) Schedule 2.14(iii) sets forth a list of all the
Intellectual Property of Sure domain names owned by Sure. Sure has full and
complete ownership of all patents.

         2.15 TAXES. Except as set out by attached schedule, all required tax
returns or federal, state, county, municipal, local, foreign and other taxes and
assessments have been properly prepared and filed by Sure for all years for
which such returns are due unless an extension for filing any such return has
been properly prepared and filed. Any and all federal, state, county, municipal,
local, foreign and other taxes, assessments, including any and all interest,
penalties and additions imposed with respect to such amounts have been paid or
provided for. The provisions for federal and state taxes reflected in the Sure
Financial Statements are adequate to cover any such taxes that may be assessed
against Sure in respect of its business and its operations during the periods
covered by the Sure Financial Statements and all prior periods.

         2.16 CORPORATE AUTHORITY. Sure has the corporate power to enter into
this Agreement and to carry out its obligations hereunder. The execution and
delivery of this Agreement by Sure have been duly authorized by its Board of
Directors, and no other

                                       6
<PAGE>

corporate proceedings on the part of Sure are necessary to approve this
Agreement or the transactions contemplated hereby.

         2.17 FULL DISCLOSURE. No representation or warranty by Sure or the Sure
Shareholders in this Agreement or in any document or schedule to be delivered by
them pursuant hereto, and no written statement, certificate or instrument
furnished or to be furnished to BioMed pursuant hereto or in connection with the
negotiation, execution or performance of this Agreement contains or will contain
any untrue statement of a material fact or omits or will omit to state any fact
necessary to make any statement herein or therein not materially misleading or
necessary to a complete and correct presentation of all material aspects of the
businesses of Sure.

SECTION 3.  REPRESENTATIONS AND WARRANTIES OF BIOMED

         BioMed hereby represents and warrants to the Sure Shareholders as
follows:

         3.1 ORGANIZATION AND GOOD STANDING. BioMed is a corporation duly
organized, validly existing and in good standing under the laws of the State of
Delaware, and is entitled to own or lease its properties and to carry on its
business as and in the places where such properties are now owned, leased, or
operated and such business is now conducted. The authorized capital stock of
BioMed consists of 40,000,000 shares of Common Stock, par value $.001 per share,
of which 4,374,350 shares are presently issued and outstanding and 10,000,000
share of Preferred Stock, par value $.001 per share, of which no shares have
been issued. BioMed is duly licensed or qualified and in good standing as a
foreign corporation where the character of the properties owned by BioMed or the
nature of the business transacted by it make such license or qualification
necessary.

         3.2 THE BIOMED SHARES. The BioMed Shares to be issued to the Sure
Shareholders have been or will have been duly authorized by all necessary
corporate and shareholder actions and, when so issued in accordance with the
terms of this Agreement, will be validly issued, fully paid and non-assessable.

         3.3 FINANCIAL STATEMENTS, BOOKS AND RECORDS. The [audited] balance
sheet of BioMed as of December 31, 2001, and statements of operations for the
periods then ended previously delivered to Sure were prepared in accordance with
generally accepted accounting principles applied on a consistent basis with
prior periods, and such financial statements fairly represent the financial
position of BioMed as at such dates and the results of its operations for the
periods then ended. The unaudited balance sheet of BioMed as 0f December 31,
2001, and statements of operations for the periods then ended previously
delivered to Sure were compiled but were not prepared in accordance with
generally accepted accounting principles applied on a consistent basis with
prior periods. However, such compiled financial statements fairly represent the
financial position of BioMed as at such dates and the results of its operations
for the periods then ended.

                                       7
<PAGE>

         3.4 NO MATERIAL ADVERSE CHANGES. Since December 31, 2001, there has not
been:

                  (i) any material adverse change in the assets, operations,
condition (financial or otherwise) or prospective business of BioMed;

                  (ii) any damage, destruction or loss materially affecting the
assets, prospective business, operations or condition (financial or otherwise)
of BioMed, whether or not covered by insurance;

                  (iii) any declaration, setting aside or payment of any
dividend or distribution with respect to any redemption or repurchase of
BioMed's capital stock;

                  (iv) any sale of an asset (other than in the ordinary course
of business) or any mortgage or pledge by BioMed of any properties or assets; or

                  (v) adoption of any pension, profit sharing, retirement, stock
bonus, stock option or similar plan or arrangement.

         3.5 COMPLIANCE WITH LAWS. BioMed has complied with all federal, state,
county and local laws, ordinances, regulations, inspections, orders, judgments,
injunctions, awards or decrees applicable to their businesses which, if not
complied with, would materially and adversely affect the business of BioMed or
the trading market for the shares of BioMed's Common Stock.

         3.6 NO BREACH. The execution, delivery and performance of this
Agreement and the consummation of the transactions contemplated hereby will not:

                  (i) violate any provision of the Articles of Incorporation or
By-Laws of BioMed;

                  (ii) violate, conflict with or result in the breach of any of
the terms of, result in a material modification of, otherwise give any other
contracting party the right to terminate, or constitute (or with notice or lapse
of time or both constitute) a default under, any contract or other agreement to
which BioMed is a party or by or to which it or any of its assets or properties
may be bound or subject;

                  (iii) violate any order, judgment, injunction, award or decree
of any court, arbitrator or governmental or regulatory body against, or binding
upon, BioMed or upon the securities properties or business of BioMed; or

                  (iv) violate any statute, law or regulation of any
jurisdiction applicable to the transactions contemplated herein.

                                       8
<PAGE>

         3.7 ACTIONS AND PROCEEDINGS. There is no outstanding order, judgment,
injunction, award or decree of any court, governmental or regulatory body or
arbitration tribunal against or involving BioMed. There is no action, suit or
claim or legal, administrative or arbitral proceeding or (whether or not the
defense thereof or liabilities in respect thereof are covered by insurance)
bankruptcy, criminal, civil or regulatory proceeding pending or threatened
against or involving BioMed or any of its properties or assets.

         3.8 BROKERS OR FINDERS. No broker's or finder's fee will be payable by
BioMed in connection with the transaction contemplated by this Agreement, nor
will any such fee be incurred as a result of any actions by BioMed.

         3.9 LIABILITIES. BioMed does not have any direct or indirect
indebtedness, liability, claim, loss, damage, deficiency, obligation or
responsibility, known or unknown, fixed or unfixed, liquidated or unliquidated,
secured or unsecured, accrued or absolute, contingent or otherwise including,
without limitation, any liability on account of taxes, any other governmental
charge or lawsuit (all of the foregoing collectively defined to as
"Liabilities"), which were not fully, fairly and adequately reflected on the
November 30, 1997 Balance Sheet. As of the Closing Date, BioMed will not have
any Liabilities, other than Liabilities fully and adequately reflected on the
December 31, 2001 Balance Sheet, except for Liabilities incurred in the ordinary
course of business.

         3.10 OPERATIONS OF BIOMED. Except as set forth on Schedule 3.10, since
December, 2001, and through the Closing Date hereof, BioMed has not and will not
have:

                  (i) incurred any indebtedness for borrowed money;

                  (ii) declared or paid any dividend or declared or made any
distribution of any kind to any shareholder, or made any direct or indirect
redemption, retirement, purchase or other acquisition of any shares in its
capital stock;

                  (iii) made any loan or advance to any shareholder, officer,
director, employee, consultant, agent or other representative or made any other
loan or advance otherwise than in the ordinary course of business;

                  (iv) except in the ordinary course of business, incurred or
assumed any indebtedness or liability (whether or not currently due and
payable);

                  (v) disposed of any assets of BioMed except in the ordinary
course of business; or

                  (vi) issued any equity securities or rights to acquire such
equity securities except as contemplated by the Stock Purchase Agreement.

                                       9
<PAGE>

         3.11 AUTHORITY TO EXECUTE AND PERFORM AGREEMENTS. BioMed has the full
legal right and power and all authority and approval required to enter into,
execute and deliver this Agreement and to perform fully its obligations
hereunder. This Agreement has been duly executed and delivered and is the valid
and binding obligation of BioMed enforceable in accordance with its terms,
except as may be limited by bankruptcy, moratorium, insolvency or other similar
laws generally affecting the enforcement of creditors' rights. The execution and
delivery of this Agreement and the consummation of the transactions contemplated
hereby and the performance by BioMed of this Agreement, in accordance with its
respective terms and conditions will not:

                  (i) require the approval or consent of any governmental or
regulatory body, the shareholders of BioMed, or the approval or consent of any
other person;

                  (ii) conflict with or result in any breach or violation of any
of the terms and conditions of, or constitute (or with any notice or lapse of
time or both would constitute) a default under, any order, judgment or decree
applicable to BioMed, or any instrument, contract or other agreement to which
BioMed is a party or by or to which BioMed is bound or subject; or

                  (iii) result in the creation of any lien or other encumbrance
on the assets or properties of BioMed.

         3.12 FULL DISCLOSURE. No representation or warranty by BioMed in this
Agreement or in any document or schedule to be delivered by it pursuant hereto,
and no written statement, certificate or instrument furnished or to be furnished
to Sure or the Sure Shareholders pursuant hereto or in connection with the
execution or performance of this Agreement contains or will contain any untrue
statement of a material fact or omits or will omit to state any fact necessary
to make any statement herein or therein not materially misleading or necessary
to a complete and correct presentation of all material aspects of the business
of BioMed.

SECTION 4. COVENANTS

         4.1 CORPORATE EXAMINATIONS AND INVESTIGATIONS. Prior to the Closing
Date, the parties acknowledge that they have been entitled, through their
employees and representatives, to make such investigation and verification of
the assets, properties, business and operations, books, records and financial
condition of the other, including communications with suppliers, vendors and
customers, as they each may reasonably require. No investigation by a party
hereto shall, however, diminish or waive in any way any of the representations,
warranties, covenants or agreements of the other party under this Agreement.
Consummation of this Agreement shall be subject to the fulfillment of due
diligence procedures to the reasonable satisfaction of each of the parties
hereto and their respective counsel.

                                       10
<PAGE>

         4.2 EXPENSES. Each party hereto agrees to pay its own costs and
expenses incurred in negotiating this Agreement and consummating the
transactions described herein.

         4.3 FURTHER ASSURANCES. The parties shall execute such documents and
other papers and take such further actions as may be reasonably required or
desirable to carry out the provisions hereof and the transactions contemplated
hereby. Each such party shall use its best efforts to fulfill or obtain the
fulfillment of the conditions to the Closing, including, without limitation, the
execution and delivery of any documents or other papers, the execution and
delivery of which are necessary or appropriate to the Closing.

         4.4 CONFIDENTIALITY. In the event the transactions contemplated by this
Agreement are not consummated, each of the parties hereto agree to keep
confidential any information disclosed to each other in connection therewith;
provided, however, such obligation shall not apply to information which:

                  (i) at the time of disclosure was public knowledge;

                  (ii) after the time of disclosure becomes public knowledge
(except due to the action of the receiving party); or

                  (iii) the receiving party had within its possession at the
time of disclosure.

         4.5 STOCK CERTIFICATES AND CONSIDERATION. At the Closing, the Sure
Shareholders shall have delivered the certificates representing the Sure Shares
duly endorsed (or with executed stock powers) so as to make BioMed the sole
owner thereof. At such Closing, BioMed shall issue to the Sure Shareholders the
BioMed Shares as provided herein.

         4.6 MANAGEMENT OF BIOMED. On the Closing Date, the present officers and
directors of BioMed (and any other persons) shall resign as officers and
directors of BioMed and the directors and officers designated by the Sure
Shareholders shall be elected by BioMed.

SECTION 5. SURVIVAL OF REPRESENTATIONS AND WARRANTIES OF BIOMED

         Notwithstanding any right of Sure and the Sure Shareholders fully to
investigate the affairs of BioMed, Sure and the Sure Shareholders shall have the
right to rely fully upon the representations, warranties, covenants and
agreements of BioMed contained in this Agreement or in any document delivered by
BioMed or any of its representatives, in connection with the transactions
contemplated by this Agreement. All such representations, warranties, covenants
and agreements shall survive the execution and

                                       11
<PAGE>

delivery hereof and the Closing Date hereunder for twenty-four (24) months
following the Closing.

SECTION 6.  SURVIVAL OF REPRESENTATIONS AND WARRANTIES OF THE SURE
            SHAREHOLDERS

         Notwithstanding any right of BioMed fully to investigate the affairs of
Sure, BioMed has the right to rely fully upon the representations, warranties,
covenants and agreements of Sure and the Sure Shareholders contained in this
Agreement or in any document delivered to BioMed by the latter or any of their
representatives in connection with the transactions contemplated by this
Agreement. All such representations, warranties, covenants and agreements shall
survive the execution and delivery hereof and the Closing Date hereunder for
twenty-four (24) months following the Closing.

SECTION 7.  INDEMNIFICATION

         7.1 OBLIGATION OF BIOMED TO INDEMNIFY. Subject to the limitations on
the survival of representations and warranties contained in Section 5, BioMed
hereby agrees to indemnify, defend and hold harmless Sure and the Sure
Shareholders from and against any losses, liabilities, damages, deficiencies,
costs or expenses (including interest, penalties and reasonable attorneys' fees
and disbursements) (a "Loss") based upon, arising out of or otherwise due to any
inaccuracy in or any breach of any representation, warranty, covenant or
agreement of BioMed contained in this Agreement or in any document or other
writing delivered pursuant to this Agreement.

         7.2 OBLIGATION OF SURE AND THE SURE SHAREHOLDERS TO INDEMNIFY. Subject
to the limitations on the survival of representations and warranties contained
in Section 6, Sure and the Sure Shareholders agree to indemnify, defend and hold
harmless BioMed to the extent provided for herein, from and against any Loss,
based upon, arising out of or otherwise due to any inaccuracy in or any breach
of any representation, warranty, covenant or agreement made by any of them and
contained in this Agreement or in any document or other writing delivered
pursuant to this Agreement.

SECTION 8.  THE CLOSING

         The Closing shall take place simultaneously with the execution hereof.
At the Closing, the parties shall provide each other with such documents as may
be necessary or appropriate and customary in transactions of this sort in order
to consummate the transactions contemplated hereby including evidence of due
authorization of the Agreement and the transactions contemplated hereby.

                                       12
<PAGE>

SECTION 9.  MISCELLANEOUS

         9.1 WAIVERS. The waiver of a breach of this Agreement or the failure of
any party hereto to exercise any right under this Agreement shall in no event
constitute waiver as to any future breach whether similar or dissimilar in
nature or as to the exercise of any further right under this Agreement.

         9.2 AMENDMENT. This Agreement may be amended or modified only by an
instrument of equal formality signed by the parties or the duly authorized
representatives of the respective parties.

         9.3 ASSIGNMENT. This Agreement is not assignable except by operation of
law.

         9.4 NOTICES. Until otherwise specified in writing, the mailing
addresses of both parties of this Agreement shall be as follows:

         SURE:                     SURE MEDICAL INCORPORATED
                                   3509 Cord Grass Drive
                                   Valrico, FL 33594

         BIOMED:                   BIOMED RESEARCH TECHNOLOGIES, INC.
                                   10150 Hignland Manor Drive, Suite 200
                                   Tampa, Florida 33610

         TRANSFER AGENT:           Manhattan Transfer Registrar, Co.
                                   58 Dorchester Road
                                   Lake Ronkonkomo, NY 11779
                                   Attn: Hector Cruz

Any notice or statement given under this Agreement shall be deemed to have been
given if sent by registered mail addressed to the other party at the address
indicated above or at such other address which shall have been furnished in
writing to the addressor.

         9.5 GOVERNING LAW. This Agreement shall be construed, and the legal
relations be the parties determined, in accordance with the laws of the State of
Florida, thereby precluding any choice of law rules which may direct the
application of the laws of any other jurisdiction.

         9.6 PUBLICITY. No publicity release or announcement concerning this
Agreement or the transactions contemplated hereby shall be issued by either
party hereto at any time from the signing hereof without advance approval in
writing of the form and substance thereof by the other party.

                                       13
<PAGE>

         9.7 ENTIRE AGREEMENT. This Agreement (including the Exhibits and
Schedules hereto) and the collateral agreements executed in connection with the
consummation of the transactions contemplated herein contain the entire
agreement among the parties with respect to the purchase and issuance of the
Sure Shares and the BioMed Shares and related transactions, and supersede all
prior agreements, written or oral, with respect thereto.

         9.8 HEADINGS. The headings in this Agreement are for reference purposes
only and shall not in any way affect the meaning or interpretation of this
Agreement.

         9.9 SEVERABILITY OF PROVISIONS. The invalidity or unenforceability of
any term, phrase, clause, paragraph, restriction, covenant, agreement or other
provision of this Agreement shall in no way affect the validity or enforcement
of any other provision or any part thereof.

         9.10 COUNTERPARTS. This Agreement may be executed in any number of
counterparts, each of which when so executed, shall constitute an original copy
hereof, but all of which together shall consider but one and the same document.

                                       14
<PAGE>

         IN WITNESS WHEREOF, the parties have executed this Agreement on the
date first above written.

                                         BIOMED RESEARCH TECHNOLOGIES, INC.

                                         By: /s/ AHMAD MORADI
                                            -----------------------------------
                                            Ahmad Moradi, President

                                         SURE MEDICAL INCORPORATED

                                         By:/s/ STEVEN ROSNER
                                            -----------------------------------
                                            Steven Rosner, President

SHAREHOLDERS:

/s/ DR. WILLIAM STAFFORD
-------------------------------------------------
My-Tech, Inc.

/s/ KIMBERLY OLENEACK
-------------------------------------------------
Kimberly Oleneack

/s/ ANDRES ALFARO
-------------------------------------------------
Andres Alfaro

/s/ RONALD GOEDDAEUS
-------------------------------------------------
Ronald Goeddaeus

/s/ FRED JAY BENDER
-------------------------------------------------
Fred Jay Bender

/s/ ELDI DESCHAMPS
-------------------------------------------------
Resources Trust Co TTEE IRA FBO Eldi Deschamps

/s/ ELDI DESCHAMPS
-------------------------------------------------
ELdi E. Deschamps TTEE Denise C. Deschamps

/s/ XXXXXXXX
-------------------------------------------------
The CEA Team

/s/ DR JAMES CAFFERY
-------------------------------------------------
University of North Texas

                                       15
<PAGE>

                                    EXHIBIT A

                     EXCHANGE WITH SURE MEDICAL INCORPORATED

                                                                   SHARES OF
NAME OF                                                           BIOMED TO
SHAREHOLDER                                                       BE RECEIVED
-----------                                                       -----------

My-Tech, Inc.                                                      3,230,000
Kimberly Oleneack                                                     10,000
Andres Alfaro                                                         10,000
Ronald Goeddaeus                                                       4,000
Fred Jay Bender                                                       50,000
Resources Trust Co TTEE

   IRA FBO Eldi Deschamps                                            375,000
Eldi E. Deschamps TTEE
   Denise C. Deschamps                                                40,000
The CEA Team                                                          11,250
University of North Texas                                          1,000,000
                                                                   ---------
GRAND TOTAL:                                                       4,730,250
                                                                   =========

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}]]